Skip to content
Open access

Formulation, Development, and Evaluation of Fast-Disintegrating Tablets of Meloxicam Solid Dispersion for Enhanced Solubility and Dissolution

Oct 2026 · International Journal of Drug Delivery Technology · 0 citations

Abstract

Introduction: Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) with poor aqueous solubility (BCS Class II) which exhibits dissolution limited absorption. The use of solid dispersion technology along with fast disintegrating tablets is a promising way to enhance its pharmaceutical properties. Aim: To formulate, develop, and evaluate fast-disintegrating tablets containing meloxicam solid dispersion for enhanced aqueous solubility and in vitro drug dissolution. Methodology: Meloxicam–Poloxamer 188 solid dispersions were prepared at drug-to-polymer ratios of 1:1, 1:2, and 1:3 using the solvent evaporation method. The drug content, saturation solubility, drug/excipient compatibility, and solid-state properties were characterized of prepared dispersions using UV spectrophotometry, FTIR, DSC and XRD. Seven formulations of fast disintegrating tablets (F1–F7) were prepared by direct compression and tested for pre compression and post compression parameters, disintegration time, in vitro dissolution and accelerated stability. Results: The solid dispersion 1:2 had the highest saturation solubility of 0.44 ± 0.03 mg/mL in phosphate buffer (pH 6.8) which is around 11 times higher than that of pure meloxicam (0.040 mg/mL). There was no major incompatibility as revealed by FTIR and XRD indicated reduced crystallinity. Formulation F2 had the fastest disintegration time (36.63 ± 0.32 seconds), drug content of 99.12 ± 0.12%, and maximum cumulative drug release of 97.18 ± 2.84% in 60 minutes. The accelerated stability testing of three months showed that the drug release was still 96.09 ± 1.71%. Conclusion: Using Poloxamer 188 as a solid dispersion technique was able to increase the solubility of meloxicam, and the optimized fast disintegration tablet showed good dissolution and short term stability. Further in vivo investigations are necessary to establish bioavailability improvements.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.